View Financial HealthMedical Developments International 배당 및 자사주 매입배당 기준 점검 0/6Medical Developments International 현재 배당금을 지급하지 않습니다.핵심 정보0%배당 수익률0%자사주 매입 수익률총 주주 수익률0%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향0%최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Feb 16Medical Developments International Limited to Report First Half, 2026 Results on Feb 19, 2026Medical Developments International Limited announced that they will report first half, 2026 results on Feb 19, 2026공시 • Sep 22Medical Developments International Limited Announces Board ChangesMedical Developments International Limited announced the appointment of Mr. Mark Fladrich as Chair of the Board, effective 1 December 2025. Mr. Fladrich succeeds Mr. Gordon Naylor, who will step down as Chair and resign from the Board on the same date. Mr. Fladrich joined the Board in April 2025 and brings over 30 years of experience in the international pharmaceutical industry. His career includes senior leadership roles at global companies, where he has demonstrated exceptional commercial, strategic, and operational expertise across a broad range of therapeutic areas, including pain management. He currently also serves as Chair of QBiotics, an Australian unlisted public life sciences company focused on oncology and wound healing therapies. During his executive career, Mr. Fladrich was Chief Commercial Officer at Grunenthal, a privately owned German company specialising in pain management. In that role, he led the global commercial organisation, expanded the company's presence into the US, and relaunched a key pain treatment in that market. Prior to joining Grunenthal, Mr. Fladrich spent 23 years at AstraZeneca. Mr. Fladrich held several senior roles there including Vice President Global Strategic Marketing, Country President roles in Germany, Australia and New Zealand and Regional Head of Southern and Western Europe. Mr. Naylor has served as a Director and Chair of the Board since October 2020. He currently holds several other governance roles, including Chair of the Board Audit and Risk Committee at Orica Limited and Chair-elect of CSL Seqirus which is anticipated to be demerged from CSL later this financial year. Mr. Naylor remains a shareholder of MVP, holding approximately 1% of MVP's issued stock. As part of its governance considerations, the Board has also taken the opportunity to create a Deputy Chair role and has appointed the Chair of Audit and Risk Committee, Mr. Paul Townsend, to that position. Mr. Townsend joined the Board in May 2025 and has brought a wealth of knowledge to MVP given his distinguished CFO career spanning multiple sectors.공시 • Aug 20Medical Developments International Limited, Annual General Meeting, Oct 10, 2025Medical Developments International Limited, Annual General Meeting, Oct 10, 2025.공시 • Aug 13Medical Developments International Limited to Report Fiscal Year 2025 Results on Aug 21, 2025Medical Developments International Limited announced that they will report fiscal year 2025 results on Aug 21, 2025공시 • Feb 12Medical Developments International Limited to Report First Half, 2025 Results on Feb 20, 2025Medical Developments International Limited announced that they will report first half, 2025 results on Feb 20, 2025공시 • Nov 14Medical Developments International Limited Announces Resignation of Mary Sontrop from the Board, Effective December 20, 2024On November 14, 2024, Medical Developments International Limited announced the resignation of Mary Sontrop from the board effective from December 20, 2024. The company announced, Mary has made a significant contribution to the Company over her 4-year tenure on the Board.공시 • Sep 03Medical Developments International Limited, Annual General Meeting, Oct 24, 2024Medical Developments International Limited, Annual General Meeting, Oct 24, 2024.공시 • Jul 28Medical Developments International Limited has filed a Follow-on Equity Offering in the amount of AUD 10.012039 million.Medical Developments International Limited has filed a Follow-on Equity Offering in the amount of AUD 10.012039 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 14,605,263 Price\Range: AUD 0.38 Discount Per Security: AUD 0.019 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 11,742,207 Price\Range: AUD 0.38 Discount Per Security: AUD 0.019 Transaction Features: Rights Offering; Subsequent Direct Listing공시 • Jul 12Medical Developments International Limited to Report Q4, 2024 Results on Aug 26, 2024Medical Developments International Limited announced that they will report Q4, 2024 results on Aug 26, 2024공시 • Feb 28Medical Developments International Limited to Report First Half, 2024 Results on Feb 29, 2024Medical Developments International Limited announced that they will report first half, 2024 results on Feb 29, 2024공시 • Sep 11Medical Developments International Limited, Annual General Meeting, Oct 27, 2023Medical Developments International Limited, Annual General Meeting, Oct 27, 2023. Agenda: To consider the election of Directors.공시 • Aug 31Medical Developments International Limited Appoints Russell Basser to the Board Effective 1 September 2023Medical Developments International Limited announced the appointment of Dr Russell Basser to the Board effective 1 September 2023. Dr Basser is a qualified physician, with over 30 years of international medical and biopharmaceutical experience. Dr Basser's worked as a medical oncologist in Melbourne prior to joining CSL in 2001. During his 21 years at CSL, he held multiple global executive roles, including Head of Global Clinical Development, Chief Medical Officer and Senior VP of Research and Development for CSL Seqirus. Dr Basser has substantial expertise in international drug and vaccine development and spent several years based in the USA. Dr Basser currently serves as a non-executive director on the Boards of Starpharma Holdings Limited andDoherty Clinical Trials. He has previously served on the Board of the ANZ Breast Cancer Trials Group and the Hadassah Australia Medical Research Collaboration.공시 • Aug 15Medical Developments International Limited to Report Fiscal Year 2023 Results on Aug 31, 2023Medical Developments International Limited announced that they will report fiscal year 2023 results on Aug 31, 2023공시 • Feb 06Medical Developments International Limited to Report First Half, 2023 Results on Feb 24, 2023Medical Developments International Limited announced that they will report first half, 2023 results on Feb 24, 2023공시 • Jan 19Medical Developments International Limited Discontinues China Clinical TrialsMedical Developments International Limited announced that it has discontinued the preparation of clinical trials for Penthrox in China. This follows extended delays to the anticipated timeline for clinical trial outcomes and consequently the commercial launch of Penthrox in the market, primarily due to the challenging regulatory environment and COVID restrictions.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 MDDV.F 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: MDDV.F 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Medical Developments International 배당 수익률 vs 시장MDDV.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (MDDV.F)0%시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Pharmaceuticals)2.1%분석가 예측 (MDDV.F) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 MDDV.F 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 MDDV.F 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: MDDV.F US 시장에서 주목할만한 배당금을 지급하지 않습니다.주주 현금 배당현금 흐름 범위: MDDV.F 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 18:33종가2026/05/06 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Medical Developments International Limited는 3명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Martyn JacobsBell PotterMartyn JacobsCanaccord GenuityDan HurrenMST Financial Services Pty Limited
공시 • Feb 16Medical Developments International Limited to Report First Half, 2026 Results on Feb 19, 2026Medical Developments International Limited announced that they will report first half, 2026 results on Feb 19, 2026
공시 • Sep 22Medical Developments International Limited Announces Board ChangesMedical Developments International Limited announced the appointment of Mr. Mark Fladrich as Chair of the Board, effective 1 December 2025. Mr. Fladrich succeeds Mr. Gordon Naylor, who will step down as Chair and resign from the Board on the same date. Mr. Fladrich joined the Board in April 2025 and brings over 30 years of experience in the international pharmaceutical industry. His career includes senior leadership roles at global companies, where he has demonstrated exceptional commercial, strategic, and operational expertise across a broad range of therapeutic areas, including pain management. He currently also serves as Chair of QBiotics, an Australian unlisted public life sciences company focused on oncology and wound healing therapies. During his executive career, Mr. Fladrich was Chief Commercial Officer at Grunenthal, a privately owned German company specialising in pain management. In that role, he led the global commercial organisation, expanded the company's presence into the US, and relaunched a key pain treatment in that market. Prior to joining Grunenthal, Mr. Fladrich spent 23 years at AstraZeneca. Mr. Fladrich held several senior roles there including Vice President Global Strategic Marketing, Country President roles in Germany, Australia and New Zealand and Regional Head of Southern and Western Europe. Mr. Naylor has served as a Director and Chair of the Board since October 2020. He currently holds several other governance roles, including Chair of the Board Audit and Risk Committee at Orica Limited and Chair-elect of CSL Seqirus which is anticipated to be demerged from CSL later this financial year. Mr. Naylor remains a shareholder of MVP, holding approximately 1% of MVP's issued stock. As part of its governance considerations, the Board has also taken the opportunity to create a Deputy Chair role and has appointed the Chair of Audit and Risk Committee, Mr. Paul Townsend, to that position. Mr. Townsend joined the Board in May 2025 and has brought a wealth of knowledge to MVP given his distinguished CFO career spanning multiple sectors.
공시 • Aug 20Medical Developments International Limited, Annual General Meeting, Oct 10, 2025Medical Developments International Limited, Annual General Meeting, Oct 10, 2025.
공시 • Aug 13Medical Developments International Limited to Report Fiscal Year 2025 Results on Aug 21, 2025Medical Developments International Limited announced that they will report fiscal year 2025 results on Aug 21, 2025
공시 • Feb 12Medical Developments International Limited to Report First Half, 2025 Results on Feb 20, 2025Medical Developments International Limited announced that they will report first half, 2025 results on Feb 20, 2025
공시 • Nov 14Medical Developments International Limited Announces Resignation of Mary Sontrop from the Board, Effective December 20, 2024On November 14, 2024, Medical Developments International Limited announced the resignation of Mary Sontrop from the board effective from December 20, 2024. The company announced, Mary has made a significant contribution to the Company over her 4-year tenure on the Board.
공시 • Sep 03Medical Developments International Limited, Annual General Meeting, Oct 24, 2024Medical Developments International Limited, Annual General Meeting, Oct 24, 2024.
공시 • Jul 28Medical Developments International Limited has filed a Follow-on Equity Offering in the amount of AUD 10.012039 million.Medical Developments International Limited has filed a Follow-on Equity Offering in the amount of AUD 10.012039 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 14,605,263 Price\Range: AUD 0.38 Discount Per Security: AUD 0.019 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 11,742,207 Price\Range: AUD 0.38 Discount Per Security: AUD 0.019 Transaction Features: Rights Offering; Subsequent Direct Listing
공시 • Jul 12Medical Developments International Limited to Report Q4, 2024 Results on Aug 26, 2024Medical Developments International Limited announced that they will report Q4, 2024 results on Aug 26, 2024
공시 • Feb 28Medical Developments International Limited to Report First Half, 2024 Results on Feb 29, 2024Medical Developments International Limited announced that they will report first half, 2024 results on Feb 29, 2024
공시 • Sep 11Medical Developments International Limited, Annual General Meeting, Oct 27, 2023Medical Developments International Limited, Annual General Meeting, Oct 27, 2023. Agenda: To consider the election of Directors.
공시 • Aug 31Medical Developments International Limited Appoints Russell Basser to the Board Effective 1 September 2023Medical Developments International Limited announced the appointment of Dr Russell Basser to the Board effective 1 September 2023. Dr Basser is a qualified physician, with over 30 years of international medical and biopharmaceutical experience. Dr Basser's worked as a medical oncologist in Melbourne prior to joining CSL in 2001. During his 21 years at CSL, he held multiple global executive roles, including Head of Global Clinical Development, Chief Medical Officer and Senior VP of Research and Development for CSL Seqirus. Dr Basser has substantial expertise in international drug and vaccine development and spent several years based in the USA. Dr Basser currently serves as a non-executive director on the Boards of Starpharma Holdings Limited andDoherty Clinical Trials. He has previously served on the Board of the ANZ Breast Cancer Trials Group and the Hadassah Australia Medical Research Collaboration.
공시 • Aug 15Medical Developments International Limited to Report Fiscal Year 2023 Results on Aug 31, 2023Medical Developments International Limited announced that they will report fiscal year 2023 results on Aug 31, 2023
공시 • Feb 06Medical Developments International Limited to Report First Half, 2023 Results on Feb 24, 2023Medical Developments International Limited announced that they will report first half, 2023 results on Feb 24, 2023
공시 • Jan 19Medical Developments International Limited Discontinues China Clinical TrialsMedical Developments International Limited announced that it has discontinued the preparation of clinical trials for Penthrox in China. This follows extended delays to the anticipated timeline for clinical trial outcomes and consequently the commercial launch of Penthrox in the market, primarily due to the challenging regulatory environment and COVID restrictions.